These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26939004)

  • 1. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
    Sjöblom L; Saramäki O; Annala M; Leinonen K; Nättinen J; Tolonen T; Wahlfors T; Nykter M; Bova GS; Schleutker J; Tammela TL; Lilja H; Visakorpi T
    PLoS One; 2016; 11(3):e0150241. PubMed ID: 26939004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.
    FitzGerald LM; Zhang X; Kolb S; Kwon EM; Liew YC; Hurtado-Coll A; Knudsen BS; Ostrander EA; Stanford JL
    Hum Mutat; 2013 Jan; 34(1):149-56. PubMed ID: 22887727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
    Dahlman A; Edsjö A; Halldén C; Persson JL; Fine SW; Lilja H; Gerald W; Bjartell A
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):369-75. PubMed ID: 20680031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
    Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
    Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
    Whitaker HC; Kote-Jarai Z; Ross-Adams H; Warren AY; Burge J; George A; Bancroft E; Jhavar S; Leongamornlert D; Tymrakiewicz M; Saunders E; Page E; Mitra A; Mitchell G; Lindeman GJ; Evans DG; Blanco I; Mercer C; Rubinstein WS; Clowes V; Douglas F; Hodgson S; Walker L; Donaldson A; Izatt L; Dorkins H; Male A; Tucker K; Stapleton A; Lam J; Kirk J; Lilja H; Easton D; ; ; ; Cooper C; Eeles R; Neal DE
    PLoS One; 2010 Oct; 5(10):e13363. PubMed ID: 20967219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.
    Lou H; Li H; Yeager M; Im K; Gold B; Schneider TD; Fraumeni JF; Chanock SJ; Anderson SK; Dean M
    Hum Genet; 2012 Sep; 131(9):1453-1466. PubMed ID: 22661295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MSMB gene rs10993994 polymorphism increases the risk of prostate cancer.
    Peng T; Zhang L; Zhu L; Mi YY
    Oncotarget; 2017 Apr; 8(17):28494-28501. PubMed ID: 28212531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
    Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
    Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.
    Xu X; Valtonen-André C; Sävblom C; Halldén C; Lilja H; Klein RJ
    Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):2035-42. PubMed ID: 20696662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
    Whitaker HC; Warren AY; Eeles R; Kote-Jarai Z; Neal DE
    Prostate; 2010 Feb; 70(3):333-40. PubMed ID: 19790236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
    Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
    Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression.
    Xu B; Wang J; Tong N; Mi Y; Min Z; Tao J; Li P; Cheng G; Li J; Wang M; Tang J; Song N; Zhang Z; Zhang W; Wu H; Hua L; Feng N
    Prostate; 2010 Jul; 70(10):1146-52. PubMed ID: 20333697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis.
    Dahlman A; Rexhepaj E; Brennan DJ; Gallagher WM; Gaber A; Lindgren A; Jirström K; Bjartell A
    Mod Pathol; 2011 May; 24(5):708-19. PubMed ID: 21240253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
    Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
    Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
    Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
    Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer.
    Yeager M; Deng Z; Boland J; Matthews C; Bacior J; Lonsberry V; Hutchinson A; Burdett LA; Qi L; Jacobs KB; Gonzalez-Bosquet J; Berndt SI; Hayes RB; Hoover RN; Thomas G; Hunter DJ; Dean M; Chanock SJ
    Hum Genet; 2009 Dec; 126(6):743-50. PubMed ID: 19644707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.
    Lou H; Yeager M; Li H; Bosquet JG; Hayes RB; Orr N; Yu K; Hutchinson A; Jacobs KB; Kraft P; Wacholder S; Chatterjee N; Feigelson HS; Thun MJ; Diver WR; Albanes D; Virtamo J; Weinstein S; Ma J; Gaziano JM; Stampfer M; Schumacher FR; Giovannucci E; Cancel-Tassin G; Cussenot O; Valeri A; Andriole GL; Crawford ED; Anderson SK; Tucker M; Hoover RN; Fraumeni JF; Thomas G; Hunter DJ; Dean M; Chanock SJ
    Proc Natl Acad Sci U S A; 2009 May; 106(19):7933-8. PubMed ID: 19383797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.